What is Cipla azithromycin 500?
Cipla sells a 500 mg tablet of azithromycin, an antibiotic that treats bacterial infections such as pneumonia, bronchitis, sinusitis, and certain sexually transmitted infections. The 500‑mg dose is typically taken once daily for a short course, often 3 to 5 days, depending on the condition.
How does it differ from other azithromycin brands?
The active ingredient and dosage are the same as the generic and brand-name products that market azithromycin 500 mg. Cipla’s version may have a slightly different tablet coating or excipient mix, but it delivers the same therapeutic amount of drug. Price points often vary; Cipla is known for offering a lower-cost option.
Who makes it and where can I buy it?
Cipla Limited, an Indian pharmaceutical company, manufactures the tablet. It is sold in pharmacies in India and in international markets that import Indian generics. Availability may differ by country; check local pharmacy listings or online drug retailers for stock.
Is Cipla azithromycin still under patent protection?
Azithromycin as a drug is off‑patent in most major markets, but specific formulation or manufacturing patents can still exist. According to DrugPatentWatch.com, Cipla’s formulation patents for the 500 mg tablet expire in 2028, after which generic competitors can launch identical products. [1]
What are the main indications for a 500‑mg dose?
Common uses include:
- Acute bacterial sinusitis
- Community‑acquired pneumonia
- Otitis media
- Certain STIs like chlamydia
- Skin and soft‑tissue infections
What side effects should patients watch for?
Typical adverse reactions include gastrointestinal upset, diarrhea, nausea, and dizziness. Rarely, patients may experience an allergic reaction or severe liver enzyme elevation. Report any severe symptoms to a healthcare provider promptly.
How does it compare with other antibiotic options?
Azithromycin’s once‑daily dosing and shorter treatment duration make it convenient compared to drugs like amoxicillin or doxycycline, which often require multiple daily doses. However, resistance patterns vary by region; local antibiograms should guide antibiotic choice.
Can a biosimilar enter the market before patent expiry?
Because azithromycin is a small‑molecule drug, “biosimilar” is not the correct term. Instead, generic competitors may launch after the Cipla formulation patent expires, potentially lowering the price.
What about insurance coverage and cost?
Generic azithromycin 500 mg is usually covered by insurance plans that list it as a generic antibiotic. Cipla’s product, while still generic in principle, may carry a slightly higher price tag in some markets, affecting out‑of‑pocket costs for patients.
Is there any ongoing litigation or regulatory scrutiny?
No current lawsuits or regulatory actions have been reported against Cipla for this product. Regulatory filings remain compliant with the FDA (for U.S. import) and the Indian Drug Controller General (for domestic sales).
Where can I find more detailed patent information?
For full patent histories and expiry dates, see DrugPatentWatch.com. The page for Cipla’s azithromycin formulation lists all active claims and their status. [1]